Inhibition of HCV 3a core gene through Silymarin and its fractions

Usman Ali Ashfaq, Tariq Javed, Sidra Rehman, Zafar Nawaz, Sheikh Riazuddin

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Hepatitis C is a major health problem affecting 270 million individuals in world including Pakistan. Current treatment regimen, interferon alpha and ribavirin only cure half of patients due to side effects and high cost. Results: In the present study Silybum marianum (Milk thistle) seeds were collected, extracted and analyzed against HCV 3a core gene by transiently transfecting the liver cells with HCV core plasmid. Our results demonstrated that Silymarin (SM) dose dependently inhibit the expression or function of HCV core gene at a non toxic concentration while the GAPDH remained constant. To identify the active ingredient, SM was fractioned by thin layer chromatography (TLC), column chromatography and HPLC. Purified fractions were tested for HCV core gene and western blotting results showed that two factions of SM (S1 and S2) inhibit HCV 3a core expression or function in liver cells. Conclusion: Our results suggest SM and its fractions (S1 and S2) inhibit HCV core gene of 3a genotype and combination of SM and its fractions with interferon will be a better option to treat HCV infection.

Original languageEnglish
Article number153
JournalVirology Journal
Volume8
DOIs
StatePublished - Apr 5 2011

Fingerprint

Silymarin
Milk Thistle
Genes
Ribavirin
Poisons
Liver
Pakistan
Hepatitis C
Thin Layer Chromatography
Interferon-alpha
Interferons
Chromatography
Seeds
Plasmids
Western Blotting
Genotype
High Pressure Liquid Chromatography
Costs and Cost Analysis
Health
Infection

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

Inhibition of HCV 3a core gene through Silymarin and its fractions. / Ashfaq, Usman Ali; Javed, Tariq; Rehman, Sidra; Nawaz, Zafar; Riazuddin, Sheikh.

In: Virology Journal, Vol. 8, 153, 05.04.2011.

Research output: Contribution to journalArticle

Ashfaq, Usman Ali ; Javed, Tariq ; Rehman, Sidra ; Nawaz, Zafar ; Riazuddin, Sheikh. / Inhibition of HCV 3a core gene through Silymarin and its fractions. In: Virology Journal. 2011 ; Vol. 8.
@article{e0cb6dbb3165484ea83d9b2635909ba3,
title = "Inhibition of HCV 3a core gene through Silymarin and its fractions",
abstract = "Hepatitis C is a major health problem affecting 270 million individuals in world including Pakistan. Current treatment regimen, interferon alpha and ribavirin only cure half of patients due to side effects and high cost. Results: In the present study Silybum marianum (Milk thistle) seeds were collected, extracted and analyzed against HCV 3a core gene by transiently transfecting the liver cells with HCV core plasmid. Our results demonstrated that Silymarin (SM) dose dependently inhibit the expression or function of HCV core gene at a non toxic concentration while the GAPDH remained constant. To identify the active ingredient, SM was fractioned by thin layer chromatography (TLC), column chromatography and HPLC. Purified fractions were tested for HCV core gene and western blotting results showed that two factions of SM (S1 and S2) inhibit HCV 3a core expression or function in liver cells. Conclusion: Our results suggest SM and its fractions (S1 and S2) inhibit HCV core gene of 3a genotype and combination of SM and its fractions with interferon will be a better option to treat HCV infection.",
author = "Ashfaq, {Usman Ali} and Tariq Javed and Sidra Rehman and Zafar Nawaz and Sheikh Riazuddin",
year = "2011",
month = "4",
day = "5",
doi = "10.1186/1743-422X-8-153",
language = "English",
volume = "8",
journal = "Virology Journal",
issn = "1743-422X",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Inhibition of HCV 3a core gene through Silymarin and its fractions

AU - Ashfaq, Usman Ali

AU - Javed, Tariq

AU - Rehman, Sidra

AU - Nawaz, Zafar

AU - Riazuddin, Sheikh

PY - 2011/4/5

Y1 - 2011/4/5

N2 - Hepatitis C is a major health problem affecting 270 million individuals in world including Pakistan. Current treatment regimen, interferon alpha and ribavirin only cure half of patients due to side effects and high cost. Results: In the present study Silybum marianum (Milk thistle) seeds were collected, extracted and analyzed against HCV 3a core gene by transiently transfecting the liver cells with HCV core plasmid. Our results demonstrated that Silymarin (SM) dose dependently inhibit the expression or function of HCV core gene at a non toxic concentration while the GAPDH remained constant. To identify the active ingredient, SM was fractioned by thin layer chromatography (TLC), column chromatography and HPLC. Purified fractions were tested for HCV core gene and western blotting results showed that two factions of SM (S1 and S2) inhibit HCV 3a core expression or function in liver cells. Conclusion: Our results suggest SM and its fractions (S1 and S2) inhibit HCV core gene of 3a genotype and combination of SM and its fractions with interferon will be a better option to treat HCV infection.

AB - Hepatitis C is a major health problem affecting 270 million individuals in world including Pakistan. Current treatment regimen, interferon alpha and ribavirin only cure half of patients due to side effects and high cost. Results: In the present study Silybum marianum (Milk thistle) seeds were collected, extracted and analyzed against HCV 3a core gene by transiently transfecting the liver cells with HCV core plasmid. Our results demonstrated that Silymarin (SM) dose dependently inhibit the expression or function of HCV core gene at a non toxic concentration while the GAPDH remained constant. To identify the active ingredient, SM was fractioned by thin layer chromatography (TLC), column chromatography and HPLC. Purified fractions were tested for HCV core gene and western blotting results showed that two factions of SM (S1 and S2) inhibit HCV 3a core expression or function in liver cells. Conclusion: Our results suggest SM and its fractions (S1 and S2) inhibit HCV core gene of 3a genotype and combination of SM and its fractions with interferon will be a better option to treat HCV infection.

UR - http://www.scopus.com/inward/record.url?scp=79953238831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953238831&partnerID=8YFLogxK

U2 - 10.1186/1743-422X-8-153

DO - 10.1186/1743-422X-8-153

M3 - Article

C2 - 21453551

AN - SCOPUS:79953238831

VL - 8

JO - Virology Journal

JF - Virology Journal

SN - 1743-422X

M1 - 153

ER -